Atlas Trials

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Clinical trial NCT04699838 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04699838
Sponsor
Muhammad Furqan
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Extensive Stage Small Cell Lung Cancer
Start date
2021-04-20
Primary completion
2026-07-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.